Pascal R D Clephas
Overview
Explore the profile of Pascal R D Clephas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
112
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ertman M, van der Valk Bouman E, Clephas P, Birkenhager T, Klimek M
J ECT
. 2024 Aug;
41(1):17-26.
PMID: 39105589
Postictal agitation (PIA) is an adverse effect of electroconvulsive therapy (ECT) and is known to predict other side effects of ECT, but inconsistencies in the literature remain regarding PIA prognostic...
2.
Allach Y, Barry-Loncq de Jong M, Clephas P, van Gent M, Brunner-La Rocca H, Szymanski M, et al.
Eur J Heart Fail
. 2024 Jun;
26(8):1736-1744.
PMID: 38825743
Aims: Heart failure (HF), a global pandemic affecting millions of individuals, calls for adequate predictive guidance for improved therapy. Congestion, a key factor in HF-related hospitalizations, further underscores the need...
3.
Malgie J, Wilde M, Clephas P, Emans M, Koudstaal S, Schaap J, et al.
Eur J Heart Fail
. 2024 May;
26(7):1549-1560.
PMID: 38734980
Aims: Despite clear guideline recommendations for initiating four drug classes in all patients with heart failure (HF) with reduced ejection fraction (HFrEF) and the availability of rapid titration schemes, information...
4.
Clephas P, Zwartkruis V, Malgie J, van Gent M, Brunner-La Rocca H, Szymanski M, et al.
Eur Heart J
. 2024 May;
45(32):2954-2964.
PMID: 38733175
Background And Aims: In patients with chronic heart failure (HF), the MONITOR-HF trial demonstrated the efficacy of pulmonary artery (PA)-guided HF therapy over standard of care in improving quality of...
5.
Mokri H, Clephas P, de Boer R, van Baal P, Brugts J, Molken M
Eur J Heart Fail
. 2024 Apr;
26(5):1189-1198.
PMID: 38560762
Aims: Remote haemodynamic monitoring with an implantable pulmonary artery (PA) sensor has been shown to reduce heart failure (HF) hospitalizations and improve quality of life. Cost-effectiveness analyses studying the value...
6.
Brugts J, Aydin D, Clephas P, de Boer R
Lancet
. 2024 Mar;
403(10429):808-809.
PMID: 38431345
No abstract available.
7.
Clephas P, Malgie J, Schaap J, Koudstaal S, Emans M, Linssen G, et al.
ESC Heart Fail
. 2023 Dec;
11(1):550-559.
PMID: 38064176
Aims: Current heart failure (HF) guidelines recommend to prescribe four drug classes in patients with HF with reduced ejection fraction (HFrEF). A clear challenge exists to adequately implement guideline-directed medical...
8.
Malgie J, Clephas P, Brunner-La Rocca H, de Boer R, Brugts J
Heart Fail Rev
. 2023 Jun;
28(5):1221-1234.
PMID: 37311917
Multiple landmark trials have helped to advance the treatment of heart failure with reduced ejection fraction (HFrEF) significantly over the past decade. These trials have led to the introduction of...
9.
Brugts J, Radhoe S, Clephas P, Aydin D, van Gent M, Szymanski M, et al.
Lancet
. 2023 May;
401(10394):2113-2123.
PMID: 37220768
Background: The effect of haemodynamic monitoring of pulmonary artery pressure has predominantly been studied in the USA. There is a clear need for randomised trial data from patients treated with...
10.
Clephas P, Radhoe S, Boersma E, Gregson J, Jhund P, Abraham W, et al.
Eur Heart J
. 2023 May;
44(37):3658-3668.
PMID: 37210750
Aims: Adjustment of treatment based on remote monitoring of pulmonary artery (PA) pressure may reduce the risk of hospital admission for heart failure (HF). We have conducted a meta-analysis of...